Chapter 13 / Managing the Clinical Trial Lifecycle / Paid beta preview

Chapter 13: Enrollment and Retention

How enrollment and retention reveal whether the protocol, sites, and participant strategy are viable. ## Activation Is Not Enrollment DIAB-220 reached first patient in because the startup work held. Sites were activated, staff were trained, the electronic data capture system (EDC), electronic clinical outcome assessment tool (eCOA), and interactive response technology system (IRT) were live, study drug was released, the trial master file [ICH E6(R3)] (TMF) had its launch documents, and patient-facing recruitment and informed consent [FDA Informed Consent 2023] materials had been approved. Lauren Brooks wanted to enjoy that milestone for more than one afternoon. By the second enrollment call, the dashboard already looked uncomfortable. Twelve sites were activated. Seven were open to recruitment, meaning they could begin identifying and approaching possible participants. Four had pre-screened patients, which meant they had done early checks using records or basic questions before full protocol screening. Two participants had signed the approved informed consent [FDA Informed Consent 2023] form (ICF) after the informed consent process [FDA Informed Consent 2023]. One participant had been randomized [ICH E9], meaning assigned by chance through IRT to one of the trial arms. "So the trial is open," Lauren said, looking at the dashboard, "but it is not really enrolling." Maggie Chen nodded. "Now you are meeting the difference between readiness and reality." In Chapter 12, DIAB-220 proved that the team could launch the trial without pretending unfinished startup work was complete. Chapter 13 asks a harder question: can the study find eligible people ethically, help them understand the trial, enroll or randomize them correctly, and retain them long enough to generate reliable evidence? Recruitment is the set of approved activities used to identify and attract possible participants. Enrollment is a person's agreement to participate after informed consent [FDA Informed Consent 2023], although some sponsors also track randomization separately as the operational enrollment target. Retention is keeping participants engaged in planned visits, assessments, and follow-up while respecting their right to withdraw. Those definitions matter because a project manager can get lost if every number is called "enrollment." An activated site is not an enrolling site. A referral is not a consented participant. A consented participant is not always randomized [ICH E9]. A randomized [ICH E9] participant is not automatically retained. A completed participant is not the same as a participant who stopped treatment but continued follow-up. Lauren wrote one sentence at the top of her notebook: > Enrollment is a funnel, not a count. ## The ENROLL Frame Maggie asked Lauren to use a simple operating frame for every enrollment conversation: | Letter | Meaning | PM Question | |---|---|---| | E | Eligibility Reality | Are the people we planned for actually findable and qualifying? | | N | Numbers and Forecasts | Are planning assumptions being replaced by real screening data? | | R | Recruitment Channels | Which approved outreach paths are ethical, effective, and usable by sites? | | O | Obstacles and Burden | What keeps patients from consenting, enrolling, or staying? | | L | Local Site Execution | Which sites need coaching, resources, escalation, or replacement? | | L | Longitudinal Retention | How do we protect follow-up, endpoint visits, safety, and participant trust? | The frame kept Lauren from reducing enrollment management to "ask sites to try harder." It forced the team to ask where the funnel was breaking and which accountable owner could change the condition. The project manager did not independently change eligibility criteria, advertising language, consent content, patient payments, statistical assumptions, or diversity targets. Those decisions belonged to Medical, Biostatistics, Regulatory, Ethics, Legal, Patient Engagement, Clinical Operations, sponsor leadership, the clinical research organization (CRO), vendors, investigators, and institutional review boards or independent ethics committees (IRBs/IECs). Lauren's job was to make the problem visible, connect the right owners, quantify risk, keep actions moving, and escalate decisions before the plan failed silently. ## Activated, Open, Screening, Enrolled, Retained Rafael Ortiz joined the next call with a table instead of reassurance. "Site enthusiasm is useful," he said. "It is not capacity. We need to separate states." | State | Plain Meaning | What The PM Should Ask | |---|---|---| | Activated | The site has met sponsor requirements to begin trial activity | What, exactly, is the site allowed to do now? | | Open to recruitment | The site can use approved pathways to identify and approach possible participants | Are recruitment materials, referral routes, and coordinator workflows actually ready? | | Pre-screening | The site checks obvious fit before full screening, often using routine records or basic questions | Are pre-screening rules clear, ethical, and privacy-compliant? | | Screening | The protocol-defined eligibility assessment begins after required consent for research-only procedures | Which criteria are failing, and are failures expected or preventable? | | Enrolled or randomized [ICH E9] | A participant agrees to participate and, where applicable, is assigned to a study arm | Are we tracking the right metric: consented, enrolled, or randomized [ICH E9]? | | Retained | Participants continue planned visits, assessments, safety follow-up, and endpoint collection | What burden, trust, safety, or

...